Literature DB >> 10634243

Pallidotomy and quality of life in patients with Parkinson's disease: an early study.

P Martínez-Martín1, F Valldeoriola, J L Molinuevo, F A Nobbe, J Rumià, E Tolosa.   

Abstract

The purpose of this study was to analyze the effect of stereotactic neurophysiologically guided pallidotomy on health-related quality of life (QoL) of patients with Parkinson's disease (PD). Eleven patients with PD (seven men, four women; mean age, 57.2 years; mean duration of disease, 14 years) with motor complications refractory to medical therapy underwent unilateral pallidotomy. Clinical assessment was carried out a week before surgery and 4 months after the surgical procedure and was based on the Core Assessment Program for Intracerebral Transplantations protocol. QoL was measured by means of the PDQ-39. A set of rating scales (Hoehn & Yahr, Unified Parkinson's Disease Rating Scale, Schwab and England, Northwestern University Disability Scale of Walking, Abnormal Involuntary Movement Scale), timed tests, and self-evaluations of motor function and mood were applied. Improvement was found in dyskinesias (74%) and off-period disability (42%). Cardinal motor signs improved significantly (30%-59%). Four dimensions of the PDQ-39 (Mobility, ADL, Emotions, Bodily Pain) showed a significant improvement (p <0.01-0.001). The global effect on QoL, measured through the PDQ-39 Summary Index (35.3%; 95% confidence interval: 15.60-54.97), was also significant (p<0.01) but unrelated to major clinical changes. Pallidotomy significantly improves QoL in patients with advanced PD. QoL measurement provides relevant information that is probably not attainable by clinical assessment.

Entities:  

Mesh:

Year:  2000        PMID: 10634243     DOI: 10.1002/1531-8257(200001)15:1<65::aid-mds1011>3.0.co;2-y

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

Review 1.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Pathophysiology of somatosensory abnormalities in Parkinson disease.

Authors:  Antonella Conte; Nashaba Khan; Giovanni Defazio; John C Rothwell; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

3.  Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine.

Authors:  Eric H Chudler; Ying Lu
Journal:  Brain Res       Date:  2008-04-08       Impact factor: 3.252

4.  Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.

Authors:  Francesc Valldeoriola; María José Catalán; Francisco Escamilla-Sevilla; Eric Freire; Jesús Olivares; Esther Cubo; Diego Santos García; Matilde Calopa; Pablo Martínez-Martín; Juan Carlos Parra; Gloria Arroyo; José Matías Arbelo
Journal:  NPJ Parkinsons Dis       Date:  2021-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.